Table 1.
IL-18 in renal disease models.
| Disease Model | Intervention | Outcome | References |
|---|---|---|---|
| AKI Model | |||
| IRI | IL-18 BP | Protective | (68) |
| IRI | IL-18-deficient | Protective | (69) |
| LPS | IL-18Rα-deficient | Protective | (70) |
| Cisplatin | Anti-IL-18 antibodies | Not protective | (71) |
| Cisplatin | Overexpression of IL-18BP | Not protective | (71) |
| Cisplatin | IL-18-deficient | Protective | (72) |
| Cisplatin | IL-18Rα-deficient | Detrimental | (73) |
| CKD Model | |||
| Anti-GBM GN | IL-18-deficient | Protective | (74) |
| Immune complex GN | IL-18Rα-deficient | Protective | (75) |
| LN (MRL/lpr) | IL-18 | Detrimental | (76) |
| LN (MRL/lpr) | IL-18Rα-deficient | Protective | (77) |
| LN (MRL/lpr) | IL-18-deficient | Protective | (78) |
| LN (MRL/lpr) | Anti-IL-18 autoantibodies (IL-18 vaccination) | Protective | (79) |
| UUO | Overexpression of IL-18BP | Protective | (80) |
| UUO | IL-18Rα-deficient | Protective | (81) |
IL, interleukin; IRI, ischemia-reperfusion injury; BP, binding protein; LPS, lipopolysaccharide; GBM, glomerular basement membrane; GN, glomerulonephritis; LN, lupus nephritis; UUO, unilateral ureteral obstruction.